Catherine A. Stedman
Christchurch, CAN, New Zealand
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Delphi survey to explore core curriculum for training the next-generation of hepatologists☆.
Journal: JHEP reports : innovation in hepatology
Published: December 10, 2025
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
Journal: Hepatology (Baltimore, Md.)
Published: February 05, 2018
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Journal: The New England journal of medicine
Published: January 25, 2018
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
Journal: Gastroenterology
Published: February 22, 2016
Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.
Journal: Hepatology international
Published: July 03, 2015
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Journal: Gastroenterology
Published: December 12, 2014
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
Journal: Gastroenterology
Published: October 03, 2013
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.
Journal: The New England journal of medicine
Published: January 04, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026